中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
5-6,7
,共3页
重组人生长激素%特发性矮小%临床疗效%生长速率%骨龄
重組人生長激素%特髮性矮小%臨床療效%生長速率%骨齡
중조인생장격소%특발성왜소%림상료효%생장속솔%골령
recombinant human growth hormone%idioPathic short stature%clinical efficacy%growth rate%bone age
目的：探讨重组人生长激素治疗儿童特发性矮小的临床疗效及安全性。方法选择2012年1月至2013年8月医院收治的特发性矮小症患儿102例，随机分为对照组和观察组，各51例。两组患儿均予改善生活习惯、加强营养物质摄入等对症治疗，对照组加用生长胶囊，观察组加用重组人生长激素治疗。结果治疗后，观察组患儿的身高和生长速率均显著高于对照组（ P＜0.05）。治疗后两组患儿骨龄变化均属于生理增长范围，组间无明显差异（ P ＞0.05）。观察组患儿的年龄身高标准差积分和骨龄身高标准差积分均显著改善( P ＜0.05)，对照组无显著改善（ P＞0.05）。两组患者不良反应发生率无显著性差异（ P＞0.05）。结论重组人生长激素治疗特发性矮小疗效确切，过程安全，同时不会造成骨龄的增长加速。
目的：探討重組人生長激素治療兒童特髮性矮小的臨床療效及安全性。方法選擇2012年1月至2013年8月醫院收治的特髮性矮小癥患兒102例，隨機分為對照組和觀察組，各51例。兩組患兒均予改善生活習慣、加彊營養物質攝入等對癥治療，對照組加用生長膠囊，觀察組加用重組人生長激素治療。結果治療後，觀察組患兒的身高和生長速率均顯著高于對照組（ P＜0.05）。治療後兩組患兒骨齡變化均屬于生理增長範圍，組間無明顯差異（ P ＞0.05）。觀察組患兒的年齡身高標準差積分和骨齡身高標準差積分均顯著改善( P ＜0.05)，對照組無顯著改善（ P＞0.05）。兩組患者不良反應髮生率無顯著性差異（ P＞0.05）。結論重組人生長激素治療特髮性矮小療效確切，過程安全，同時不會造成骨齡的增長加速。
목적：탐토중조인생장격소치료인동특발성왜소적림상료효급안전성。방법선택2012년1월지2013년8월의원수치적특발성왜소증환인102례，수궤분위대조조화관찰조，각51례。량조환인균여개선생활습관、가강영양물질섭입등대증치료，대조조가용생장효낭，관찰조가용중조인생장격소치료。결과치료후，관찰조환인적신고화생장속솔균현저고우대조조（ P＜0.05）。치료후량조환인골령변화균속우생리증장범위，조간무명현차이（ P ＞0.05）。관찰조환인적년령신고표준차적분화골령신고표준차적분균현저개선( P ＜0.05)，대조조무현저개선（ P＞0.05）。량조환자불량반응발생솔무현저성차이（ P＞0.05）。결론중조인생장격소치료특발성왜소료효학절，과정안전，동시불회조성골령적증장가속。
Objective To investigate the efficacy of recombinant human growth hormone in the treatment of idioPathic short stature in children and to evaluate its safety. Methods 102 children with idioPathic short stature from January 2012 to August 2013 in the hos-Pital were selected and randomly divided into the control grouP and the observation grouP, 51 cases in each grouP. The two grouPs were given symPtomatic treatment;the control grouP was added with Shengzhang CaPsules, and the observation grouP was added with recombi-nant human growth hormone. Results After treatment, the height and growth rate of the observation grouP were significantly higher than those of the control grouP ( P < 0. 05 ) . Changes of bone age growth in the two grouPs belonged to the normal Physiological range, and with no significant difference between the two grouPs ( P > 0. 05 ) . The age, height and standard deviation score and bone age height standard deviation score of the observation grouP imProved significantly ( P < 0. 05 ) , and the control grouP had no obvious imProvement ( P > 0. 05). There was no significant difference between the two grouPs in drug related adverse reactions( P > 0. 05). Conclusion The efficacy of recombinant human growth hormone in treating idioPathic short stature is exact with safe Process, and without the acceleration of bone growth.
